.svg)
Life Sciences Insurance: Risk Solutions for Pharma, HealthTech, MedTech, & Medical Devices
For investors and boards, the question isn’t simply whether the business has insurance. It is whether the programme accurately reflects the risks posed by the stage of development, regulations, product class, jurisdictional scope, contractual supply chain, and the severity of patient or participant harm.
Aligned with your Scientific, Operational, Clinical & Commercial Risk Profile
Life Sciences Insurance can protect businesses operating across biotechnology, pharmaceuticals, medical devices, diagnostics, digital health, clinical trials, laboratories, and contract research.
These organisations face a uniquely complex risk profile because scientific innovation, patient safety, regulatory approval, intellectual property, supply chain integrity, and product performance are often directly connected.
At Indemnity, we assist with creating a Life Sciences Insurance programme that protects the business from the laboratory stage through to commercialisation. This may include R&D property damage, clinical trial liability, product liability, medical malpractice, cyber incidents, management liability, professional indemnity, product recall, stock throughput, and business interruption.
An Evolving Insurance Programme
.svg)
Life sciences businesses evolve through distinct operational phases. A university spin-out developing early stage IP does not present the same risk as a medical device manufacturer distributing implanted products across multiple jurisdictions. The insurance programme should therefore be considered with the businesses development pathway.
The earlier the stage, the greater the focus on R&D assets, intellectual property, funding continuity, laboratory equipment, specialist materials, and research timelines. As the business moves towards human trials and commercial distribution, the focus shifts towards clinical liability, product safety, participant protection, regulatory obligations, recall, and jurisdictional litigation.
Access to Specilist Life Sciences Underwriters
The Life Sciences Blended Risk Allocation Matrix
Core Sectors & Life Science Risk Solutions
Different financial businesses carry different regulatory and operational exposures. We carefully structure insurance programmes to reflect your risk profile.
Biotechnology & Pharmaceuticals
Biotechnology and pharmaceutical companies face a blend of scientific, operational, regulatory, and financial exposures. The value of the business can be in years of research, trial data, samples, intellectual property, and investor-funded development milestones.
For a life sciences business, a freezer failure is not always a simple contents claim. It may destroy irreplaceable samples, invalidate years of research, delay trials, breach investor milestones, or force the business to repeat expensive scientific work.
Business Interruption cover should therefore be reviewed carefully. Standard gross profit calculations may not capture the true financial impact of delayed research, lost grant funding, missed development milestones, re-testing costs, specialist equipment lead times, or regulatory resubmission delays.
A suitable programme may need to include laboratory equipment cover, deterioration of stock, research and development materials, in addition to products and service liability, cyber insurance, management liability, employers’ liability, public liability, and clinical trial liability, where applicable.
Medical Devices
Medical device companies require specialist insurance because product performance can directly affect patient safety. The risk profile changes significantly depending on device classification, intended use, invasiveness, software dependency, and whether the device is implanted, diagnostic, therapeutic, or monitoring-based.
A Class I consumable, a Class II diagnostic tool, and a Class III implanted device do not create the same severity of exposure. For high-risk implanted devices, such as pacemakers, orthopaedic implants, implantable monitors, or other long-term invasive products, claims can involve serious injury, revision surgery, collective actions, regulatory intervention, product withdrawal.
For software, the exposure may sit between product liability, technology E&O, cyber, and medical malpractice. A defective algorithm, failed alert, inaccurate diagnostic output, or integration error may create patient harm even where there is no physical manufacturing defect.
Medical device businesses should not rely on generic Product Liability Insurance. The policy should be reviewed for design defect, software related injury, clinical use, recall costs, global jurisdiction, regulatory defence, and whether the insurer understands the product category.
Digital HealthTech & MedTech
Digital health and HealthTech businesses combine software, data, clinical workflows, patient interaction, and medical decision support. These firms may not manufacture a physical product, but their technology can still influence diagnosis, triage, monitoring, treatment, referral, or patient behaviour.
This creates a hybrid exposure between Technology E&O, Cyber Insurance, Medical Malpractice, and Product Liability.
Digital health insurance may be relevant for telemedicine platforms, remote triage tools, symptom checker applications, AI-assisted diagnostic tools, clinical decision support software;
digital therapeutics, electronic health record platforms, healthcare SaaS providers;
Potential claims may involve algorithmic misdirection, failed escalation, inaccurate patient advice, system downtime, personal data breach, software integration failure, clinical workflow errors, and patient injury linked to technology failure.
For HealthTech firms, the insurance programme must clarify where software liability ends and clinical liability begins. This is especially important where the platform is used by clinicians, employers, insurers, patients, or healthcare providers to support care decisions. Explore our dedicated specialist HealthTech and digital health insurance guidance.
CRO's and Labs
Contract Research Organisations, laboratories, academic research partners, and outsourced testing providers are critical to the life sciences supply chain. They may not own the product, but their professional services can influence trial outcomes, regulatory submissions, and safety decisions.
CROs and labs should pay close attention to contractual risk management. Sponsor agreements may contain broad indemnities, service-level obligations, confidentiality duties, data protection obligations, audit rights, and liability caps that need to be reviewed against the insurance programme.
For laboratories, business interruption and research materials cover can be critical. Specialist testing equipment, refrigeration systems, reagents, samples, and validated processes may take significant time to replace or restore after a loss.
A specialist programme should reflect both the professional service exposure and the physical laboratory dependency.
Clinical Trials Protection
Clinical trials create one of the more sensitive risks in life sciences. Sponsors, contract research organisations, investigators, laboratories, and healthcare providers may all interact across a trial structure, but the sponsor often carries central responsibility for ensuring that appropriate insurance and indemnity arrangements are in place.
Clinical Trial Insurance is designed to protect against claims arising from injury to participants during a trial. Depending on the territory, protocol, ethics requirements, and local law, cover may need to address both negligent harm and no-fault compensation.
This is particularly important because trial participants may suffer injury even where no party is legally negligent. Industry guidance and local requirements may require compensation pathways for participants harmed by trial participation.
Market Access: A-Rated Capacity
Our Framework: Technical Market Presentation
Different businesses require different risk architecture depending on whether they are developing therapies, manufacturing devices, operating laboratories, managing trials, providing digital health infrastructure, or supporting the wider healthcare ecosystem.
Broker Advisory Services
Life Sciences Insurance requires a specialist broker because scientific, clinical, regulatory, digital, and product risks can often overlap.
Our role is to help life sciences companies compare more than premium. We assess whether the insurance programme reflects the science, the product, the patient exposure, the data, the contracts, and the commercial pathway.
For life sciences businesses, a single failure can affect patients, investors, regulators, research timelines, and future commercial viability. A suitable insurance programme should protect the enterprise from lab bench to commercial scale.
Claim Advocacy Guide
Broker claim advocacy is particularly important in the life sciences sector because claims often involve complex scientific, clinical, regulatory, contractual, and causation issues.
A single incident may trigger multiple policy sections. Our role is to help present the claim clearly, coordinate insurer engagement, protect your position, and ensure that technical evidence is properly understood.
For biotech, pharma, medical device, HealthTech, CRO, and laboratory businesses, effective claim advocacy can be critical to avoiding coverage disputes, accelerating insurer response, and preserving commercial momentum when a serious allegation, product failure, participant injury, cyber incident, or R&D loss occurs.
Read more about our claim advocacy guidance.
Claims Paid
Fair Value Statement
Fair value assessments consider the relationship between the price paid by the client and the quality of the insurance products and services provided.
For Life Science businesses, fair value means arranging insurance solutions that are suitable for the client’s risk profile, competitively structured, and consistent with the expectations of the FCA Consumer Duty.
Frequently Asked
Questions
Does Cyber Insurance matter for life sciences companies?
Yes. Life sciences businesses often hold sensitive patient data, research data, trial records, intellectual property, regulatory documents, and trade secrets. Coverage under a cyber policy can help with ransomware, data breaches, forensic investigation, legal advice, regulatory defence, data restoration, cyber extortion, business interruption, and privacy liability claims.
What is Product Recall Insurance?
Product Recall Insurance can help cover costs associated with recalling, withdrawing, replacing, testing, or communicating about a defective or unsafe product. For life sciences companies, recall exposure can be severe where medical devices, diagnostics, biologics, pharmaceuticals, or healthcare products are distributed across multiple territories.
Does Life Sciences Insurance cover intellectual property disputes?
Some life sciences programmes may include limited intellectual property defence or infringement cover, but this varies significantly. Patent disputes, licensing conflicts, trade secrets, collaboration agreements, and ownership disputes often need specialist review.
Businesses relying heavily on IP should not assume their Professional Indemnity is sufficient. Standalone IP policies can provide broader cover and also allow for proactive measures to mitigate the risks of third parties from infringing upon your IP.
Meet the Brokers
.webp)
